Effect of Repeated Oral Administrations of the Oral Adsorbent AST-120 on Serum Creatinine and Other Markers of Renal Function
Authors:
- Jean-Francois MarierJMJean-Francois Marier
- James LeeJLJames Lee
- Siva Rama Prasad KambhampatiSKSiva Rama Prasad Kambhampati
- Lawrence GalitzLGLawrence Galitz
- Ramon VargasRVRamon Vargas
- James MoberlyJMJames Moberly
- Daniel E. SalazarDSDaniel E. Salazar
- 1 May 2006
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 26 (2) , 136-141
Abstract
Background: AST-120 is an orally administered adsorbent used in Japan for prolonging time to initiation of hemodialysis and improving uremic symptoms in patients with chronic kidney disease (CKD). As AST-120 is suspected to reduce the progression of CKD by adsorbing renal toxins in the gastrointestinal tract, the objective of the current study was to determine whether binding of AST-120 to creatinine in the intestines could acutely alter creatinine balance, thereby limiting the utility of serum creatinine (sCr) as a measure of progression of renal function. Such information may be critical for the design of future studies to assess the efficacy of AST-120 in CKD patients. Methods: Patients with CKD (n = 20) received oral doses of AST-120(3 g t.i.d.) and placebo in a two-way crossover study. Blood and urine were collected for determination of sCr, 24-hour urinary creatinine (UcrV), creatinine clearance (Ccr), and urea nitrogen clearance (URCL). Differences between treatments were assessed using an ANCOVA model. Results: Following AST-120 and placebo treatments, mean sCr (1.73 and 1.79 mg/dl, respectively) and UcrV (1,264.73 and 1,286.05 mg) values were not significantly different. No significant differences were observed for Ccr and URCL. Conclusion: These results indicate that AST-120 has no acute impact on creatinine balance in patients with CKD. Consequently, sCr and other markers of renal function are acceptable measures for assessing changes in renal function following AST-120 treatment.Keywords
This publication has 11 references indexed in Scilit:
- Protective Effect of an Oral Adsorbent on Renal Function in Chronic Renal Failure: Determinants of its Efficacy in Diabetic NephropathyTherapeutic Apheresis and Dialysis, 2004
- Effect of Oral Adsorbent (AST-120) on Renal Function, Acquired Renal Cysts and Aortic Calcification in Rats with Adriamycin NephropathyNephron, 2002
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic ratsAmerican Journal of Kidney Diseases, 2001
- Effect of Oral Adsorbent on the Progression of Diabetic NephropathyNephron, 1997
- Dietary Protein Loading and the Oral Adsorbent AST-120 in the Progression of Chronic Renal Failure in the RatThe International Journal of Artificial Organs, 1992
- Inhibitory Effect of Oral Sorbent on Accumulation of Albumin-Bound Indoxyl Sulfate in Serum of Experimental Uremic RatsNephron, 1991
- A Study of Oral Adsorbent in Chronic Renal FailureBiomaterials, Artificial Cells and Immobilization Biotechnology, 1991
- Therapeutic Effects of Oral Sorbent in Undialyzed UremiaAmerican Journal of Kidney Diseases, 1988